Comparison of GW (908) Single Dose and Steady-state Pharmacokinetics (PK): Induction Potential and AAG Changes (APV10013)

Similar documents
Clinical Study Report AI Final 28 Feb Volume: Page:

GSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:

Clinical Study Synopsis for Public Disclosure

INDIVIDUAL STUDY TABLE REFERRING TO PART OF THE DOSSIER

Jennifer R King, Amit Khatri, Roger Trinh, Bifeng Ding, Jiuhong Zha and Rajeev Menon AbbVie Inc.

Median (Min Max) CVC 100 mg + EFV placebo + TDF/FTC (N=8) CVC 200 mg + EFV placebo + TDF/FTC (N=10) LLOQ=5.00 ng/ml Time (h)

The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.

Clinical Study Synopsis for Public Disclosure

Generic lopinavir/ritonavir is bioequivalent to Aluvia but neither result in adequate lopinavir exposure at 50% dose reduction: HIV-NAT 085

The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.

Effect of Multiple-Dose Ketoconazole and the Effect of Multiple-Dose Rifampin on Pharmacokinetics (PK) of the HCV NS3 Protease Inhibitor Asunaprevir

Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, Illinois 60064

Clinical Pharmacology of DAA s for HCV: What s New & What s In Pipeline

Single and Multiple Dose Pharmacokinetics and Safety in Non-HIV-Infected Healthy Subjects Dosed with BMS , an Oral HIV Attachment Inhibitor

Evaluation of Drug-Drug Interactions Between Sofosbuvir/Velpatasvir/Voxilaprevir and Boosted or Unboosted HIV Antiretroviral Regimens

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not

Study Centers: This study was conducted in 2 centers in Italy.

New Insights on the Pharmacokinetics of Ulifloxacin After Administration of Prulifloxacin in Patients with Mild, Moderate and Severe Renal Impairment

SINGLE-DOSE AND STEADY-STATE PHARMACOKINETICS OF MOXDUO, A DUAL-OPIOID FORMULATION CONTAINING A FIXED RATIO OF MORPHINE AND OXYCODONE

Effect of Daclatasvir/Asunaprevir/Beclabuvir in Fixed-dose Combination on the Pharmacokinetics of CYP450/Transporter Substrates In Healthy Subjects

Clinical Study Synopsis for Public Disclosure

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

Poster O_16. Merck Sharp & Dohme Corp., Whitehouse Station, NJ, USA; 2. Lifetree Clinical Research, Salt Lake City, UT, USA

Effect of Fosamprenavir/Ritonavir on the Pharmacokinetics of Dolutegravir in

The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not

Module Summary of Clinical Pharmacology

Pharmacokinetics and Drug Interaction Profile of Cobicistat boosted-elvitegravir with Atazanavir, Rosuvastatin or Rifabutin

Clinical Study Synopsis for Public Disclosure

Principal Investigator: Marion, Alan, S, M.D., MDS Pharma Services (US) Inc., 621 Rose Street, PO Box 80837, Lincoln, NE 68502, USA

Kimberly Adkison, 1 Lesley Kahl, 1 Elizabeth Blair, 1 Kostas Angelis, 2 Herta Crauwels, 3 Maria Nascimento, 1 Michael Aboud 1

Noncompartmental Analysis (NCA) in PK, PK-based Design

Clinical Study Synopsis for Public Disclosure

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

Helmut Schütz. The Global Bioequivalence Harmonisation Initiative. 12 April 2018 [Session II: Necessity of multiple dose studies in BE testing] 1

The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not

Single-Dose and Multiple-Dose Pharmacokinetics of Vaniprevir in Healthy Men

Erik Mogalian, Polina German, Chris Yang, Lisa Moorehead, Diana Brainard, John McNally, Jennifer Cuvin, Anita Mathias

Background: Narlaprevir (SCH )

Dr. M.Mothilal Assistant professor

Effect of Food on the Pharmacokinetics of the Integrase Inhibitor Dolutegravir

2.0 Synopsis. ABT-333 M Clinical Study Report R&D/09/956

PAGE Meeting 2003 Verona, Italy

Drug-Drug Interactions that Matter

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

Regulatory experience in application of modelling in dose selection

What are the most promising opportunities for dose optimisation?

Merck Sharp & Dohme Corp., The Netherlands; Merck Sharp & Dohme Corp., Whitehouse Station, NJ, USA; Yale University, New Haven, CT, USA;

Public Assessment Report. Scientific discussion. Ropinirol Actavis. Ropinirole hydrochloride DK/H/1212/ /DC

Clinical Study Synopsis for Public Disclosure

Pharmacologic Characteristics and Delivery Options for Integrase Inhibitors

Modified Release: C min C τ. Modified Release

Protease Inhibitor Therapy: Boosted and Double-Boosted Options to the Fore

Study No: Title : Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Statistical Methods:

Selected Properties of Fosamprenavir. Telzir, Lexiva (US), GW ViiV Healthcare ULC

The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.

The management of HIV-1 protease inhibitor pharmacokinetic interactions

Clinical Study Synopsis for Public Disclosure

Drug-Drug Interaction Study of Ketoconazole and Ritonavir-boosted Saquinavir ACCEPTED

Clinical Study Synopsis for Public Disclosure

PHARMACOKINETICS OF ANTIRETROVIRAL AND ANTI-HCV AGENTS

43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) A Cutrell, J Hernandez, M Edwards, J Fleming, W Powell, T Scott

These results are supplied for informational purposes only.

Study No: LOV OMA-104 Title : Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Statistical Methods

A novel ph-neutral formulation of the monomeric insulin VIAject has a faster onset of action than insulin lispro

Pediatric Patient Information:

Section 3.F and Section 6 Human Pharmacokinetics and Bioavailability

Drug Interactions Between Direct-Acting anti-hcv Antivirals Sofosbuvir and Ledipasvir and HIV Antiretrovirals

Bristol-Myers Squibb HCV DAAs: Review of Interactions Involving Transporters. Timothy Eley. 21 May 2014

Cohort 2. Age, years 41.0 (10.2) Diabetes duration, years 26.5 (15.8)

Principal Investigator. Study center(s) This was a single-center study. Publications None at the time of writing this report.

Merck Sharp & Dohme Corp., Whitehouse Station, NJ, USA. 8 th International Workshop on Clinical Pharmacology of Hepatitis Therapy June 2013

Sponsor / Company: Sanofi Drug substance: SAR236553/REGN727 (alirocumab)

IPAC-RS/UF Orlando Inhalation Conference March 20, S.T. Horhota 1, C.B. Verkleij 2, P.J.G. Cornelissen 2, L. Bour 3, A. Sharma 3, M.

Received 21 December 2012; returned 4 January 2013; revised 19 February 2013; accepted 23 February 2013

Clinical Study Synopsis for Public Disclosure

The Effect of Mild and Moderate Hepatic Impairment on Telaprevir Pharmacokinetics

GSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:

Drug Interactions with ART and New TB drugs: What Do We Know?

PHA Spring First Exam. 8 Aminoglycosides (5 points)

Maraviroc Pharmacokinetics in Blood Plasma, Genital Tract Fluid and Tissue in Healthy Female Volunteers

Effects of Gender, Race, Age & BMI on the Pharmacokinetics of Long-Acting Rilpivirine (RPV-LA) after a Single IM Injection in HIV negative subjects.

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

ICVH 2016 Oral Presentation: 28

Section 5.2: Pharmacokinetic properties

1. If the MTC is 100 ng/ml and the MEC is 0.12 ng/ml, which of the following dosing regimen(s) are in the therapeutic window?

SYNOPSIS OF RESEARCH REPORT (PROTOCOL BC20779)

Supplementary Table 1: Summary of 33 Patients Treated with Abemaciclib in Dose Escalation

Integrase Strand Transfer Inhibitors on the Horizon

Clinical Study Synopsis

Amit Khatri, Sandeep Thomas Marbury, Richard A Preston, Lino Rodrigues, Haoyu Wang, Walid Awni, Rajeev Menon

Rifabutin PK and Safety among HIV/TB Coinfected Children Receiving Lopinavir

Development of a protease inhibitor-based single-tablet complete HIV-1 regimen of darunavir/cobicistat/emtricitabine/tenofovir

The advent of protease inhibitors (PIs) as PROCEEDINGS CLINICAL EXPECTATIONS OF EFFICACY: PROTEASE INHIBITOR POTENCY * Benjamin Young, MD, PhD

Clinical Study Synopsis for Public Disclosure

Raltegravir (RAL) Pharmacokinetics (PK) and Safety in HIV-1 Exposed Neonates at High Risk of Infection: IMPAACT P1110

Introduction. Protease Inhibitor based ART in children is used:

Pharmacokinetic Interaction Between Norgestimate/Ethinyl Estradiol and EVG/COBI/FTC/TDF Single Tablet Regimen

SYNOPSIS. The study results and synopsis are supplied for informational purposes only.

Transcription:

43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) Poster A-1607 Comparison of GW433908 (908) Single Dose and Steady-state Pharmacokinetics (PK): Induction Potential and AAG Changes (APV10013) MB Wire, KL Baker, Y Lou, S Weller, DS Stein GlaxoSmithKline, RTP, NC Address correspondence to mary.b.wire@gsk.com Introduction 908 is a convenient (flexible dosing, no food or water restrictions) investigational protease inhibitor (PI) with demonstrated antiviral efficacy, durability, and tolerability in antiretroviral (ART)-naïve and PI-experienced subjects. 908, the phosphate ester prodrug of amprenavir (APV), is rapidly converted to APV in vivo. Time-variant plasma APV PK, characterized by reductions in plasma APV AUC values between Day 1 and Day 28, has been observed following 908 administration to HIV-infected subjects. In a Phase II 908 study, APV20001, the Day 28/Day 1 APV AUC ratios (90% CIs) for the 908 regimens were: 0.73 (0.61-0.87) for 908 1395 mg BID and 0.55 (0.47-0.66) for 908 1860 mg BID. 1 Time-variance in plasma APV PK has been correlated with reductions in plasma α-1-acid glycoprotein (AAG) concentrations, an APV binding protein, as patients receive effective antiretroviral therapy. 2 However, in the Phase II 908 study, plasma APV AUC values declined despite statistical adjustment for AAG reductions, suggesting that a mechanism other than, or in addition to, reductions in AAG is responsible for the time-variance. Mechanisms other than changes in AAG that could theoretically contribute to reduced APV exposure with multiple dosing include limitation of absorption and increased elimination through metabolic induction (CYP3A4). As part of a PK interaction study with atorvastatin (ATO), time-variance in plasma APV PK, and potential mechanisms, were further evaluated in healthy subjects.

Methods 39 healthy adults were enrolled and 26 subjects completed the study as described in Table 1. This poster presents data for the 12 subjects who received 908 1400 mg BID alone (ie, Arm 1 in Period 2) as described in Table 2. The 908-ATO PK interaction data are presented elsewhere. 3 Table 1 Study Design Period 1 Period 2 Period 3 Arm 1 ATO Washout 908 1400 mg BID ATO 10 mg QD + 21 enrolled 10 mg QD x 7-10 days x 14 days 908 1400 mg BID 12 completed x 4 days x 4 days Arm 2 ATO Washout 908 700 mg BI + ATO 10 mg QD + 18 enrolled 10 mg QD x 7-10 days RTV 100 mg BID 908 700 mg BID + 14 completed x 4 days x 14 days RTV 100 mg BID x 4 days Table 2 Study Design: Arm 1, Period 2 Details Day -1 Day 1 Days 2-13 Day 14 908 single dose 908 BID dosing 908 AM dosing 24-hour serial PK Predose PK sampling 12-hour serial PK sampling Days 3, 6, 9, 12, 13 sampling AAG concentration AAG concentration 24-hour 6β-HC/C 24-hour 6β-HC/C Serial plasma PK samples were collected on Days 1 and 14 as follows: 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, and 12 hours on both days, plus at 16 and 24 hours on Day 1. Plasma PK samples were analyzed for APV by a validated HPLC-MS-MS method. The achievement of steady state by Day 14 was assessed by calculating the 90% CI of the slope from linear regression analysis of the Day 12, 13, and 14 predose plasma APV concentrations. Day 1 and Day 14 PK parameters were estimated by noncompartmental methods and compared by ANOVA, with and without correction for AAG. Urine samples were analyzed for 6β-hydroxycortisol (6β-HC) and cortisol (C) by an HPLC-MS-MS method. The amount of each compound excreted in the urine over 24 hours (AE 0-24 ) was calculated and the ratio of these amounts (6β-HC/C ratio) was compared between Day 14 and Day 1 by ANOVA to assess potential metabolic (CYP3A4) induction by 908. Plasma AAG concentrations were compared by ANOVA.

Results Twelve (12, 100%) males and equal numbers of whites and blacks (6/12, 50%) were included in the analysis. Ages ranged from 18 to 54 years, body weights ranged from 56.3-86.9 kg, heights ranged from 165-196 cm, and BMIs ranged from 20.6 to 28.4 kg/m 2. The safety results are presented elsewhere. 3 Steady-state was achieved by Day 14 because the 90% CI from the linear regression of log-transformed plasma APV trough concentrations collected on Days 12, 13, and 14 included zero and the slope estimate was close to zero: -0.1051 (-0.3036 to 0.0933). Median Day 1 and Day 14 plasma APV concentration-time profiles are displayed in Figure 1. PK parameter estimates are presented in Table 3 and PK comparisons are presented in Table 4. The geometric mean steady-state plasma APV PK parameter values predicted from the single dose PK values assuming that PK is not time-variant were: AUCτ,ss: 19.5 h*µg/ml, C max,ss : 4.80 µg/ml, and Cτ,ss: 0.44 µg/ml. There was an unexpected 14% decrease in plasma AAG concentrations between Days 1 and 14 (Table 5). Inclusion of AAG as a covariate in the ANOVA model accounted for the lower than predicted AUC value but did not account for the lower than predicted Cτ,ss value. The C max,ss value was similar to the predicted value. Figure 1 Median Plasma APV Concentration-time Profiles Table 3 Plasma APV PK Parameter Estimates (Geometric Mean [95% CI]) Plasma APV PK Parameter Day 1 Day 14 b AUC 19.5 17.0 (h * µg/ml) a (15.0-25.4) (13.3-21.9) C max 4.00 4.52 (µg/ml) 3.11-5.14) (3.41-6.00) C 12 0.369 0.23 (µg/ml) (0.254-0.536) (0.17-0.30) a AUC for Day 1 and AUC τ,ss for Day 14 b Predicted geometric mean Day 14 AUC τ,ss = 19.5 h*µg/ml, C max,ss = 4.80 µg/ml, and C t,ss = 0.44 µg/ml

Table 4 Plasma APV PK Comparisons (Day 14/Day 1) (GLS Mean Ratio [90% CI]) Plasma APV PK Comparison Without AAG Covariate a With AAG Covariate AUC τ,ss /AUC 0.87 0.98 (0.70-1.10) (0.75-1.29) C max,ss /C max 1.13 1.29 (0.92-1.38) (1.00-1.68) C τ,ss /C 12 0.62 0.62 (0.53-0.72) (0.50-0.77) a Predicted GLS mean ratio = 1.20 for Cmax,ss and Cτ,ss Table 5 Plasma AAG Concentration Summary (Geometric Mean [95% CI]) and GLS Mean Difference (Day 14 Day 1), 95% CI Day 1 Day 14 Day 14 Day 1 75.8 65.6-11.23 (65.3-88.0) (59.2-72.7) (-20.8-1.69) AAG concentration unit = mg/dl Table 6 Urine 6β-HC/C Ratio Comparison (Day 14/Day 1) (GLS Mean Ratio [90% CI]) Day -1 Day 14 Day 14/Day -1 6.90 5.90 0.86 (0.72-1.02) Discussion The ability to evaluate the metabolic induction potential of APV in HIV-infected subjects is confounded by reductions in plasma AAG concentrations which occur as patients are effectively treated. Thus, this study was designed to evaluate single-dose and steady-state plasma APV PK in healthy adult subjects in order to gain a better understanding of the mechanism(s) resulting in time-variant plasma APV PK. There was a small, approximately 13%, decrease in plasma APV AUC over 14 days of 908 1400 mg BID dosing. There may be multiple mechanisms causing this reduction, including induction of CYP3A4, induction of P-glycoprotein, limitation of absorption, and plasma AAG changes. Despite the initial decrease in plasma APV C 12 values, plasma APV C τ,ss values were stabilized between Days 12 and 14 (ie, steady-state was achieved). It is apparent that 908 administered at a dose of 1400 mg BID is not a potent CYP3A4 inducer based on the average 14% decrease in the 24-hour urinary 6β-HC/C ratio observed in this study, rather than an increase in this ratio which would indicate induction. Conclusions There was a small, approximately 13%, decrease in plasma APV AUC over 14 days of 908 1400 mg BID dosing in healthy subjects. GW433908 is not a potent CYP3A4 inducer based on the urinary 6β-HC/C ratio. Given the inconsistent changes in the plasma APV PK parameters, the lack of evidence of CYP3A4 induction, and the inability for AAG to fully account for the plasma APV PK changes, the mechanisms responsible for time-variant plasma APV PK are likely multifactorial.

References 1. Wood R, et al. Manuscript submitted to Antimicrob Agents Chemother. 2. Sadler BM, et al. Antimicrob Agents Chemother. 2001;45(3):852-856. 3. Wire MB, et al. 43rd ICAAC. 2003. Abstract A-1622.